Main Therapeutic Uses

Artrixib is a medication classified as a non-steroidal anti-inflammatory drug (NSAID), specifically a selective COX-2 inhibitor. It is primarily used to manage symptoms associated with various forms of arthritis and other inflammatory conditions. By targeting specific enzymes in the body, it helps to reduce the chemical signals that lead to pain and swelling.

Osteoarthritis

Artrixib is indicated for the relief of signs and symptoms of osteoarthritis, a degenerative joint disease. In patients with this condition, the medication helps to manage chronic joint pain and improve physical function by reducing inflammation within the affected joints.

Rheumatoid Arthritis

For individuals with rheumatoid arthritis, an autoimmune condition, Artrixib is used to decrease joint tenderness and swelling. It assists in managing the systemic inflammation characteristic of the disease, which can help maintain joint mobility over time.

Ankylosing Spondylitis

Artrixib is also utilized in the treatment of ankylosing spondylitis, a chronic inflammatory arthritis that primarily affects the spine and sacroiliac joints. The medication helps alleviate the back pain and stiffness associated with this condition.

Benefits in Pain Management

Beyond chronic arthritic conditions, Artrixib may be used for the management of acute pain in adults. This includes the treatment of primary dysmenorrhea (menstrual pain) and short-term pain relief following surgical procedures or musculoskeletal injuries.

Mechanism of Action

The primary benefit of Artrixib lies in its selective inhibition of the COX-2 enzyme. Unlike non-selective NSAIDs, which inhibit both COX-1 and COX-2, Artrixib focuses on the enzyme primarily responsible for inflammation. This selectivity is intended to provide effective anti-inflammatory and analgesic effects while minimizing certain types of systemic interference.

Regulatory References

1. NIH MedlinePlus overview of Celecoxib uses

Who can and cannot use Artrixib?

Artrixib (Celecoxib) is a prescription-only medicine whose eligibility is strictly defined by government regulatory authorities based on age, allergies, and pre-existing medical conditions.

---

Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated for several populations to minimize serious risk:

• Patients with known allergy or hypersensitivity to celecoxib, sulfonamides, aspirin, or other NSAIDs.
• Individuals with active peptic ulceration, gastrointestinal (GI) bleeding, or Inflammatory Bowel Disease (IBD).
• Patients with severe hepatic dysfunction (Child-Pugh Class C) or severe uncontrolled heart failure.
• Use is prohibited during the third trimester of pregnancy.
• Use is prohibited for peri-operative pain in the setting of CABG surgery.

Conditional and Age-Related Eligibility

• Pediatric Use: Artrixib is indicated for Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age and older. Safety is not established for children under two.
• Organ Function: Use is not recommended for patients with severe renal impairment or those who are breastfeeding.
• Restricted Use: Patients with moderate hepatic impairment or those identified as CYP2C9 poor metabolizers require special caution and often a reduced dose.

Interactions with other medicines and products

Artrixib (Celecoxib) has several officially documented interactions that modify exposure or affect co-administered substances, as outlined in government regulatory labeling.

Contraindicated Combinations

Co-administration is formally contraindicated in the setting of peri-operative pain following CABG surgery and for patients with a known history of allergic reactions to sulfonamides or to aspirin/other NSAIDs.

Pharmacokinetic and Exposure Modifications

Interactions often center on the CYP2C9 enzyme. Strong CYP2C9 inhibitors, such as Fluconazole, are documented to significantly increase Artrixib plasma concentrations (e.g., a two-fold rise in exposure). Conversely, antacids containing aluminum or magnesium are documented to reduce Artrixib's plasma concentration. Co-administration with Lithium or Digoxin can increase the serum concentrations of these medicines.

Pharmacodynamic and Risk Reinforcement

Use with Warfarin or other oral anticoagulants carries an increased risk of serious bleeding, which requires strict monitoring. Artrixib may diminish the therapeutic effect of ACE Inhibitors, ARBs, and Diuretics. Concomitant use with other non-aspirin NSAIDs is generally avoided due to an increased risk of gastrointestinal toxicity.

Non-Drug Product Interactions

Ingesting Artrixib with a high-fat meal officially delays peak plasma levels and slightly increases total absorption. Regulatory-aligned information also documents that use with alcohol increases the risk of serious gastrointestinal side effects.

Selective Enzyme Inhibition and Prostaglandin Suppression

Artrixib functions as a selective inhibitor molecule that precisely targets and blocks the activity of the enzyme Cyclooxygenase-2 ( COX-2). This enzyme is largely responsible for generating pro-inflammatory signaling molecules and is often upregulated rapidly in cells following disturbance. The drug occupies a pocket near the enzyme's active site, preventing its ability to metabolize its natural substrate, Arachidonic Acid.

Modulation of Central and Peripheral Signaling

This inhibition suppresses the production of key local chemical messengers, known as prostaglandins, central to the pathway that drives heightened physiological responses. The mechanism acts both peripherally in local tissues and centrally within the nervous system. Artrixib modifies the activity of pathways associated with excessive physiological signaling, which involves the modulation of the central signaling pathways responsible for resetting the body's thermal set-point.

Specificity and Physiological Consequence

Artrixib's high degree of specificity for the COX-2 enzyme guides its action toward inducible pathways, rather than the constitutive processes mediated by COX-1. This targeted pathway interference results in a reduction of excessive mediator activity, leading to physiological adjustments that result from pathway interference.

How to Use Artrixib

Artrixib (celecoxib) is a prescription-only medication. Proper administration is required to ensure the intended use of the product.

---

Routes and Administration Conditions

Artrixib is administered via the oral route and is available in capsule and oral solution forms. The capsule can be taken with or without food.

Administration Specifics	Instruction
Dosing Principle	Use the lowest effective dosage for the shortest duration possible.
Swallowing Difficulty	Capsule contents may be mixed with a teaspoon of approved soft foods (e.g., applesauce or yogurt) and must be ingested immediately with water.
Oral Solution	Must be measured using a calibrated measuring device

---

Adult Dosing Regimens

The maximum recommended daily dose for all adult capsule indications is 400 mg. Dosing varies by indication and frequency:

• Osteoarthritis (OA): 200 mg once daily (QD) or 100 mg twice daily (BID).
• Rheumatoid Arthritis (RA): 100 mg to 200 mg twice daily.
• Acute Pain/Primary Dysmenorrhea: Initial dose of 400 mg, followed by 200 mg once if needed on the first day, and 200 mg BID thereafter as needed.

---

Population-Specific Use

Dose adjustments are required for certain groups. For patients with moderate hepatic impairment (Child-Pugh Class B), the recommended dose must be reduced by 50%. In pediatric patients (aged 2 years or older) with Juvenile Rheumatoid Arthritis, dosing is weight-based. Therapy should be initiated at the lowest recommended dose for elderly patients weighing less than 50 kg.

Research Evidence / Overview of Studies for Artrixib

---

Evidence for Chronic Inflammatory Conditions

The research base for this substance includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that examined outcomes related to long-term symptoms of Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. These studies explored how symptoms change over time, focusing on patient-reported outcomes describing perceived discomfort using tools like the WOMAC Index to measure physical discomfort and activity level.

Studies often compared the substance to a placebo and to other non-selective anti-inflammatory medications. Findings describe patterns observed in the studies related to measured outcomes reflecting daily functioning or activity level over defined time intervals. Some trials described patterns where measured outcomes related to physical discomfort and activity level showed variances between the substance group and the placebo group. The magnitude of these measured differences, particularly in trials comparing to other treatments, may vary across studies.

---

Evidence for Acute and Short-Term Pain

The research base examining the substance in conditions associated with acute or disruptive episodes, such as postoperative pain or Primary Dysmenorrhea, largely draws from single-dose Randomized Controlled Trials and systematic reviews. These studies monitored outcomes related to episodic or acute changes and capturing phases of heightened symptom activity.

Researchers examined specific metrics, such as the time to the first documented change in symptom intensity, and the overall magnitude of change measured over very short study periods. Data show patterns related to short-term symptom changes, based on measured outcomes describing episodic or acute changes. However, the follow-up durations were limited in these acute pain trials, meaning there is limited information for long-term outcomes.

---

Research into Specific Adjuvant Use

The research exploring this substance for Familial Adenomatous Polyposis (FAP) was studied for in specific Randomized, Placebo-controlled Studies. This research examined how the substance was associated with changes in the number and size of adenomatous polyps. Initial studies reported measured changes in polyp burden over periods of approximately six months. However, follow-up data was not fully available for regulatory review. As a result, the evidence quality varies across studies for this application, and certainty remains low in this context.

Common questions about Artrixib (FAQ)

Q: Where should I store this medication?

A: Official product information suggests storing Artrixib at room temperature, away from excessive moisture, heat, and direct light. Regulatory guidelines recommend keeping the container tightly closed and avoiding humid areas like the bathroom.

Q: Can I take this medicine with alcohol?

A: The official regulatory label advises that patients avoid or limit the consumption of alcohol while taking Artrixib. Combining this medication with alcohol may increase the risk of specific side effects, such as heightened drowsiness or dizziness.

Q: What should I do if I am pregnant or breastfeeding?

A: If you are pregnant, planning to become pregnant, or breastfeeding, it is important to consult a healthcare provider to discuss the use of this medication. The official label contains a Risk Summary detailing the potential effects, and a professional can help weigh the benefits and risks.

Q: Does this medicine cause drowsiness or affect my ability to drive?

A: Official prescribing information indicates that Artrixib may cause Central Nervous System (CNS) effects, such as sedation, dizziness, or lightheadedness. Because these effects can potentially impair judgment, caution is advised when driving or operating heavy machinery until the medication's effect is known.

Q: What is the maximum amount I can take in a day?

A: The official product information specifies a maximum daily dose for Artrixib, as well as recommended time intervals between doses. Patients are advised to consult the specific product label or their prescribing healthcare provider for guidance on the maximum recommended dosage.

Q: Can I crush or chew the tablet?

A: Regulatory information indicates that Artrixib is intended for oral use and should be swallowed whole. The product label does not authorize crushing, chewing, or breaking the tablets, as this action can potentially affect how the medicine works or is absorbed.

Official Storage and Disposal Requirements

Artrixib must be stored strictly according to the official regulatory label to ensure product stability and effectiveness.

Storage Conditions

Requirement	Official Statement
Temperature	Store at controlled room temperature, between 15°C and 30°C (59°F and 86°F).
Environment	Protect from moisture and light; store in a dry place.
Handling	Do not freeze the product and do not store above 30°C.
Packaging	Keep Artrixib in its original container, tightly closed, until the time of use.
Stability	Do not use the medicine past the expiration date printed on the container.

Disposal and Safety

For public health and environmental protection, keep this medicine out of the sight and reach of children. Expired or unused Artrixib must be disposed of through an official drug take-back program or a pharmacy collection site. Do not flush the product down the toilet or discard it into household wastewater.